The Effect of Effervescent Alendronate on Bone Turnover

Overview

64 postmenopausal women are randomized to treatment with either effervescent and buffered alendronate or conventional alendronate -both 70mg weekly for 16 weeks to see if bone turnover is suppressed to the same extent as in the conventional formulation with the effervescent form.

Full Title of Study: “The Effect of Effervescent and Buffered Alendronate on Bone Turnover Compared to Conventional Alendronate: A Randomized Non-inferiority Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 1, 2022

Detailed Description

Alendronate is mainstay in the treatment of osteoporosis but is often discontinued due to gastro-intestinal side-effects. These side effects are believed to be caused by a low gastric pH induced by the drug. Effervescent and buffered alendronate is a new formulation that increases gastric pH and thereby decreases risk of side effects but the clinical effect of the drug is not fully elucidated. In the present study 64 postmenopausal women with a bone mineral density T-score < -1 are randomized 1:1 to open label treatment with effervescent and buffered alendronate or conventional alendronate 70 mg weekly for 16 weeks. The primary end-point is change in the bone resorption marker "carboxy-terminal collagen crosslinks" from baseline to 16 weeks. The decrease in the two groups is compared using non-inferiority statistics. Secondary end-points include change in the bone formation marker "propeptide of type 1 procollagen", rate of change in the two bone markers and occurence of side effects.

Interventions

  • Drug: Conventional alendronate
    • Conventional alendronate 70mg weekly
  • Drug: Effervescent and buffered alendronate
    • Effervescent and buffered alendronate 70mg weekly

Arms, Groups and Cohorts

  • Active Comparator: Fosamax (conventional alendronate)
    • Conventional alendronate 70mg weekly for 16 weeks
  • Experimental: Binosto (effervescent and buffered alendronate)
    • Effervescent and buffered alendronate70mg weekly for 16 weeks

Clinical Trial Outcome Measures

Primary Measures

  • CTx
    • Time Frame: baseline to week 16
    • Change in the bone resorption marker CTx

Secondary Measures

  • P1NP
    • Time Frame: baseline to week 16
    • Change in the bone resorption marker P1NP

Participating in This Clinical Trial

Inclusion Criteria

  • 2 years since last menstrual bleeding – Bone mineral density T-score < -1 at either lumbar spine or hip – CTx > 0.42 µg/L Exclusion Criteria:

  • Ever treatment for osteoporosis – Indication for teriparatide treatment – Treatment with oral systemic glucocorticoids within last 12 months – Rheumatoid arthritis – Inflammatory bowel disease – Untreated thyroid disease – Primary hyperparathyroidism – Diabetes mellitus – eGFR < 60 mL/min – Cancer within last 2 years except basal cell carcinoma of the skin – Hormone therapy – Unstable liver disease – Contraindications for alendronate – Major gastrointestinal disease within 12 months (eg. esophagitis, ulcer, major surgery). – Vitamin D < 50nmol/L

Gender Eligibility: Female

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Aarhus University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Torben Harsløf, MD, PhD, consultant in endocrinology – Aarhus University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.